Abstract
Secondary bone tumours arising in the field of a preceding radiotherapy are a serious late effect, in particular considering the increasing survival times in patients treated for paediatric malignancies. In general, therapy associated tumours are known to show a more aggressive behaviour and a limited response to chemotherapy compared with their primary counterparts. It is not clear however whether this less favourable outcome is caused by inherent genetic factors of the tumour cells or by a general systemic condition of the patient. To elucidate this we analysed a series of bone sarcomas with a history of prior irradiation for the presence of genomic alterations and compared them with the alterations identified earlier in primary osteosarcomas. We analysed seven radiation induced bone sarcomas for genome-wide losses of heterozygosity (LOH) using Affymetrix 10K2 high-density single nucleotide polymorphism (SNP) arrays. Additionally, copy number changes were analysed at two distinct loci on 10q that were recently found to be of major prognostic significance in primary osteosarcomas. All the investigated tumours showed a LOH at 10q21.1 with 86% of cases (6/7) revealing a total genome-wide LOH score above 2400 and more than 24% of the genome being affected. Our results indicate similar genetic alterations in radiation induced sarcomas of bone and primary osteosarcomas with a poor prognosis. We speculate that the high degree of genomic instability found in these tumours causes the poor prognosis irrespective of the initiating event.
Keywords: Genomic instability, Loss-of-heterozygosity, Osteosarcom, Predictive assay, Radiation-induced, SNP-array, Therapy-related, Therapy response, heterozygosity, radiotherapy , induced bone sarcomas
Current Genomics
Title:Secondary Radiation-Induced Bone Tumours Demonstrate a High Degree of Genomic Instability Predictive of a Poor Prognosis
Volume: 13 Issue: 6
Author(s): Christine Rumenapp, Jan Smida, Iria Gonzalez-Vasconcellos, Daniel Baumhoer, Bernard Malfoy, Nabila-Sandra Hadj-Hamou, Bahar Sanli-Bonazzi, Michaela Nathrath, Michael J. Atkinson and Michael Rosemann
Affiliation:
Keywords: Genomic instability, Loss-of-heterozygosity, Osteosarcom, Predictive assay, Radiation-induced, SNP-array, Therapy-related, Therapy response, heterozygosity, radiotherapy , induced bone sarcomas
Abstract: Secondary bone tumours arising in the field of a preceding radiotherapy are a serious late effect, in particular considering the increasing survival times in patients treated for paediatric malignancies. In general, therapy associated tumours are known to show a more aggressive behaviour and a limited response to chemotherapy compared with their primary counterparts. It is not clear however whether this less favourable outcome is caused by inherent genetic factors of the tumour cells or by a general systemic condition of the patient. To elucidate this we analysed a series of bone sarcomas with a history of prior irradiation for the presence of genomic alterations and compared them with the alterations identified earlier in primary osteosarcomas. We analysed seven radiation induced bone sarcomas for genome-wide losses of heterozygosity (LOH) using Affymetrix 10K2 high-density single nucleotide polymorphism (SNP) arrays. Additionally, copy number changes were analysed at two distinct loci on 10q that were recently found to be of major prognostic significance in primary osteosarcomas. All the investigated tumours showed a LOH at 10q21.1 with 86% of cases (6/7) revealing a total genome-wide LOH score above 2400 and more than 24% of the genome being affected. Our results indicate similar genetic alterations in radiation induced sarcomas of bone and primary osteosarcomas with a poor prognosis. We speculate that the high degree of genomic instability found in these tumours causes the poor prognosis irrespective of the initiating event.
Export Options
About this article
Cite this article as:
Rumenapp Christine, Smida Jan, Gonzalez-Vasconcellos Iria, Baumhoer Daniel, Malfoy Bernard, Hadj-Hamou Nabila-Sandra, Sanli-Bonazzi Bahar, Nathrath Michaela, J. Atkinson Michael and Rosemann Michael, Secondary Radiation-Induced Bone Tumours Demonstrate a High Degree of Genomic Instability Predictive of a Poor Prognosis, Current Genomics 2012; 13 (6) . https://dx.doi.org/10.2174/138920212802510420
DOI https://dx.doi.org/10.2174/138920212802510420 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy Editorial [Hot topic: Bisphosphonates and Bone Diseases: Past, Present and Future (Guest Editor: Dominique HEYMANN)]
Current Pharmaceutical Design Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Antiproliferative Activity of microRNA-125a and its Molecular Targets
MicroRNA Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Non-coding RNAs as Novel Biomarkers in Cancer Drug Resistance
Current Medicinal Chemistry Merlin, a “Magic” Linker Between the Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival
Current Protein & Peptide Science Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy
Current Cancer Drug Targets Application of Microdialysis in Clinical Pharmacology
Current Clinical Pharmacology Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry Clinical and Imaging Features of Tumors in the Scapula
Current Medical Imaging Attenuation of ERK/RSK2-Driven NFκB Gene Expression and Cancer Cell Proliferation by Kurarinone, a Lavandulyl Flavanone Isolated from Sophora flavescens Ait. Roots
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of ZEB Family Members in Proliferation, Metastasis, and Chemoresistance of Prostate Cancer Cells: Revealing Signaling Networks
Current Cancer Drug Targets Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects
Current Drug Metabolism Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Current Pharmaceutical Biotechnology Osteopontin is a Prognostic Factor in Patients with Advanced Gastric Cancer
Combinatorial Chemistry & High Throughput Screening The Safety and Efficacy of Parathyroid Hormone (PTH) as a Biological Response Modifier for the Enhancement of Bone Regeneration
Current Drug Safety Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Role of Caspases, Bax and Bcl-2 in Chrysin-Induced Apoptosis in the A549 Human Lung Adenocarcinoma Epithelial Cells
Anti-Cancer Agents in Medicinal Chemistry miR-126 as a Therapeutic Agent for Diabetes Mellitus
Current Pharmaceutical Design